The 23rd China International In Vitro Diagnostic Expo (CACLP 2026) has successfully concluded. KHB, together with its subsidiary Tianlong Technology, made a strong appearance, presenting a full portfolio of innovative IVD technologies and integrated solutions.

Throughout the exhibition, the booth attracted industry experts, partners, and visitors from around the world, with continuous engagement, in-depth discussions, and strong interest in KHB’s comprehensive diagnostic offerings.

Compact Yet Powerful | mini LAS Draws Strong Attention

A key highlight of the exhibition was the Polaris mini LAS, which demonstrated how advanced automation can be achieved within a footprint of less than 1 m2. Designed for small and medium-sized laboratories, the system integrates essential automation functions to support efficient and standardized workflow upgrades.

Key features include:

- Flexible sample loading modes

- Fully automated workflow

- AI-powered intelligent recognition

- Enhanced biosafety with multi-layer protection

Mass Spectrometry Solution | Advancing Precision Medicine

KHB’s clinical mass spectrometry solution, developed in collaboration with Waters, attracted significant attention from visitors.

The ACQUITY UPLC I-Class PLUS / Xevo TQ-Long System and Xevo TQ-S cronos System, combined with the KHB Nova 9600 Fully Automated Sample Processing System, deliver high-performance detection across multiple clinical applications, including:

- Nutritional status assessment

- Therapeutic drug monitoring (TDM)

- Endocrine hormone analysis

- Newborn screening for inherited metabolic diseases

With strong capabilities in high sensitivity, specificity, and multi-analyte detection, the solution supports the advancement of precision diagnostics.

Dual Molecular Systems | Enabling True Sample-to-Result Testing

In the field of molecular diagnostics, two key systems were showcased: iGenebox 3A Automated Nucleic Acid Testing System and Aurora PANA X5 Automated Nucleic Acid Extraction System. Together, they deliver a fully automated workflow, enabling true “sample-in, result-out” operation and simplifying molecular testing processes.

Comprehensive Reagent Portfolio | Supporting Diverse Clinical Needs

KHB also presented its extensive portfolio of 900+ diagnostic reagents, covering:

- Clinical chemistry

- Immunoassay

- Molecular diagnostics

- Mass spectrometry

- POCT

Designed for seamless compatibility with KHB and Tianlong platforms, the portfolio ensures accurate, reliable, and traceable results, supporting a wide range of clinical applications.

CACLP 2026 marked another important milestone in KHB’s global journey. Through continuous innovation and collaboration, KHB Group remains committed to delivering integrated, high-quality diagnostic solutions to partners worldwide.